Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

The recommendations also put forth two new diagnosis categories: clinical obesity and pre-obesity. The first describes people with evidence of health conditions caused by excess weight, such as heart ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...